Research Articles | Page 10 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

  1. Home
  2. Research

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Phase 2 Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes Sep 2019 Clinical Cancer Research: an official Journal of the American Association of Cancer Research Myelodysplastic Syndromes (MDS)
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Mar 2021 The New England Journal of Medicine Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria Jun 2023 Blood Advances Paroxysmal Nocturnal Hemoglobinuria (PNH)
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes Oct 2023 Oncologist Myelodysplastic Syndromes (MDS)
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes Apr 2023 The Oncologist Myelodysplastic Syndromes (MDS)
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes Apr 2023 The Oncologist Myelodysplastic Syndromes (MDS)
Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab Aug 2020 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Patient stratification in myelodysplastic syndromes: how a puzzle may become a map Dec 2020 Hematology. American Society of Hematology. Education Program Myelodysplastic Syndromes (MDS)
Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. Sep 2020 PloS One Paroxysmal Nocturnal Hemoglobinuria (PNH)
Patient and physician perceptions about blood transfusions in the myelodysplastic syndromes Jul 2020 Leukemia Research Myelodysplastic Syndromes (MDS)